Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to assess the safety, tolerability, and efficacy when
combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted
in 2 phases, Phase Ib and Phase II.